<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02857270</url>
  </required_header>
  <id_info>
    <org_study_id>16419</org_study_id>
    <secondary_id>I8S-MC-JUAB</secondary_id>
    <secondary_id>2016-001907-21</secondary_id>
    <nct_id>NCT02857270</nct_id>
  </id_info>
  <brief_title>A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer</brief_title>
  <official_title>A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety of an extracellular signal regulated&#xD;
      kinase (ERK1/2) inhibitor LY3214996 administered alone or in combination with other agents in&#xD;
      participants with advanced cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 29, 2016</start_date>
  <completion_date type="Anticipated">September 10, 2022</completion_date>
  <primary_completion_date type="Actual">February 10, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with LY3214996 Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (21 Days)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration-Time Curve (AUC) of LY3214996 Administered as Monotherapy and when Administered in Combination with Nab-Paclitaxel Plus Gemcitabine, Abemaciclib and Encorafenib Plus Cetuximab</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Gemcitabine when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Nab-Paclitaxel when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 15 (28 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Abemaciclib and its Metabolites when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Encorafenib when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Cetuximab when Administered with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 2 Day 1 (up to 22 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: AUC of Midazolam and its 1'-Hydroxymidazolam Metabolite when Administered Alone and in Combination with LY3214996</measure>
    <time_frame>Cycle 1 Day 1 through Cycle 1 Day 16 (21 Day Cycles)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants With a Complete (CR) or Partial Response (PR)</measure>
    <time_frame>Baseline to Measured Progressive Disease or Start of New Anti-Cancer Therapy (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 12 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Response (TTR)</measure>
    <time_frame>Baseline to Date of CR or PR (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Progressive Disease or Death of Any Cause (Estimated up to 12 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR): Percentage of Participants who Exhibit Stable Disease (SD), CR or PR</measure>
    <time_frame>Baseline through Measured Progressive Disease (Estimated up to 6 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Dose Expansion Arms Only)</measure>
    <time_frame>Baseline to Date of Death from Any Cause (Estimated up to 2 Years)</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">245</enrollment>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Metastatic Non-small Cell Lung Cancer</condition>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>LY3214996 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally once a day (or twice a day) for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Preliminary Drug-Drug Interactions [DDI])&#xD;
LY3214996 given orally (once a day) and midazolam given orally on cycle 1 day 1 and cycle 1 day 16 (21 day cycles except cycle 1 only = 22 days).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally (once a day) during each 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Abemaciclib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and abemaciclib given orally (single dose given during lead in period) twice a day every 12 hours during 21 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Expansion- LY3214996 given orally (dose timing will be determined) and nab-paclitaxel given intravenously (IV) on day 1, 8, and 15 and gemcitabine IV on day 1, 8, and 15 during each 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose Escalation and Expansion- LY3214996 given orally, encorafenib given orally and cetuximab given IV.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japan Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Japan Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3214996 given orally and abemaciclib given orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3214996</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Japan Part 1</arm_group_label>
    <arm_group_label>Japan Part 2</arm_group_label>
    <arm_group_label>LY3214996 + Abemaciclib</arm_group_label>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
    <arm_group_label>LY3214996 + Midazolam</arm_group_label>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
    <arm_group_label>LY3214996 Dose Escalation</arm_group_label>
    <arm_group_label>LY3214996 Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3214996 + Midazolam</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abemaciclib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Japan Part 2</arm_group_label>
    <arm_group_label>LY3214996 + Abemaciclib</arm_group_label>
    <other_name>LY2835219</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3214996 + Nab-Paclitaxel + Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Encorafenib</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3214996 + Encorafenib + Cetuximab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have advanced or metastatic cancer (solid tumors) and be an appropriate candidate for&#xD;
             experimental therapy.&#xD;
&#xD;
               -  Part B (No Longer Enrolling Participants): Have advanced or metastatic cancer&#xD;
                  with an activating mitogen-activated protein kinase pathway alteration, BRAF&#xD;
                  mutant metastatic melanoma refractory to or relapsed after treatment with RAF&#xD;
                  and/or MEK inhibitors, metastatic melanoma with a NRAS mutation, or BRAF mutant&#xD;
                  NSCLC.&#xD;
&#xD;
               -  Part C: Advanced, unresectable cancer (dose escalation) and advanced,&#xD;
                  unresectable, or metastatic non-small cell lung cancer with a BRAF or RAS&#xD;
                  mutation, or NRAS mutant melanoma (dose expansion).&#xD;
&#xD;
               -  Part D (No Longer Enrolling Participants): Have metastatic pancreatic ductal&#xD;
                  adenocarcinoma (dose escalation and dose expansion).&#xD;
&#xD;
               -  Part E: Metastatic BRAF V600E colorectal cancer.&#xD;
&#xD;
          -  Have discontinued previous treatments for cancer and have resolution, except where&#xD;
             otherwise stated in the inclusion criteria, of all clinically significant toxic&#xD;
             effects of prior chemotherapy, surgery, or radiotherapy to Grade ≤1 by National Cancer&#xD;
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.&#xD;
&#xD;
          -  Have adequate organ function.&#xD;
&#xD;
          -  Have a performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG)&#xD;
             scale.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have serious preexisting medical conditions.&#xD;
&#xD;
          -  Have a known human immunodeficiency virus (HIV) infection or known&#xD;
             activated/reactivated hepatitis A, B, or C.&#xD;
&#xD;
          -  Have symptomatic central nervous system malignancy or metastasis.&#xD;
&#xD;
          -  Have current hematologic malignancies, acute or chronic leukemia.&#xD;
&#xD;
          -  Have a second primary malignancy that in the judgment of the investigator or Lilly may&#xD;
             affect the interpretation of results.&#xD;
&#xD;
          -  Have prior malignancies. Participants with carcinoma in situ of any origin and&#xD;
             participants with prior malignancies who are in remission and whose likelihood of&#xD;
             recurrence is very low, as judged by the Lilly clinical research physician, are&#xD;
             eligible for this study.&#xD;
&#xD;
          -  Have a mean QT interval corrected for heart rate (QTc) of ≥470 milliseconds on&#xD;
             screening electrocardiogram (ECG) as calculated using the Bazett's formula at several&#xD;
             consecutive days of assessment.&#xD;
&#xD;
          -  Have participated, within the last 28 days in a clinical trial involving an&#xD;
             investigational product or are currently enrolled in a clinical trial involving an&#xD;
             investigational product or any other type of medical research judged not to be&#xD;
             scientifically or medically compatible with this study.&#xD;
&#xD;
          -  Have previously completed or withdrawn from this study or any other study&#xD;
             investigating an ERK1/2 inhibitor.&#xD;
&#xD;
          -  If female, is pregnant, breastfeeding, or planning to become pregnant.&#xD;
&#xD;
          -  Have history or findings of central or branch retinal artery or venous occlusion with&#xD;
             significant vision loss or other retinal diseases that cause current visual impairment&#xD;
             or would likely cause visual impairment over the time period of the study.&#xD;
&#xD;
          -  Currently using concomitant medications that are strong inhibitors or inducers of&#xD;
             CYP3A4.&#xD;
&#xD;
          -  Part C: have serious and/or uncontrolled preexisting medical condition(s) that, in the&#xD;
             judgment of the investigator, would preclude participation in this study, including&#xD;
             interstitial lung disease (ILD) or severe dyspnea at rest or requiring oxygen therapy.&#xD;
&#xD;
          -  Part C4 NRAS Melanoma: have previously completed or withdrawn from a study&#xD;
             investigating a MEK inhibitor.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232-1305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shizuoka Cancer Center</name>
      <address>
        <city>Sunto-Gun</city>
        <state>Shizuoka</state>
        <zip>411-8777</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>104-0045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/64K6fy9q0Mw2eU8WyW2u4K</url>
    <description>A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer</description>
  </link>
  <verification_date>September 1, 2021</verification_date>
  <study_first_submitted>August 3, 2016</study_first_submitted>
  <study_first_submitted_qc>August 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2016</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MAPK</keyword>
  <keyword>RAS</keyword>
  <keyword>BRAF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

